Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

Roy M. Fleischmann*, Mark C. Genovese, Jeffrey V. Enejosa, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew Ostor, Yihan Li, In Ho Song

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

149 Citations (SciVal)

Fingerprint

Dive into the research topics of 'Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science